Help Privacy Policy Disclaimer
  Advanced SearchBrowse




Journal Article

Nitric oxide and dopamine neurons: implications for Parkinson´s disease

There are no MPG-Authors in the publication available
External Resource
Fulltext (public)
There are no public fulltexts stored in PuRe
Supplementary Material (public)
There is no public supplementary material available

Mena, M., Casarejos, M., & Canals, S. (2005). Nitric oxide and dopamine neurons: implications for Parkinson´s disease. Current Medicinal Chemistry, 5(3), 193-205. doi:10.2174/1568015054863846.

Cite as: http://hdl.handle.net/11858/00-001M-0000-0013-D429-C
There is evidence suggesting that nitric oxide (NO) may play an important role in dopamine (DA) cell death. NO may act as a neuroprotector or neurotoxic agent in dopamine neurons, depending on cell redox status. Glutathione (GSH) depletion is the earliest biochemical alteration shown to date in brains of Parkinson‘s disease (PD) patients. However, data from animal models show that GSH depletion by itself is not sufficient to induce nigral degeneration. Low NO concentrations have neurotrophic effects on DA cells via a cGMP-independent mechanism that may implicate up-regulation of GSH. On the other hand, higher levels of NO induce cell death in both DA neurons and mature oligodendrocytes that is totally reverted by soluble factors released from glia. Alterations in GSH levels change the neurotrophic effects of NO in dopamine function into neurotoxic, under these conditions, NO triggers a programmed cell death with markers of both apoptosis and necrosis characterised by an early production o f free radicals followed by late activation of the sGC/cGMP/PKG pathway. Arachidonic acid metabolism through the 12-lipoxygenase (12-LOX) pathway is also central for this GSH-NO interaction. Neurotrophism of NO switches into neurotoxicity after GSH depletion, due to persistent activation of the ERK-1/2 signaling pathway in glial cells. The implication of these cell death signaling pathways in pathological conditions like Parkinson‘s disease, where GSH depletion, glial dysfunction and NO overproduction have been documented, are discussed.